专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2019204738A1 FORMULATIONS AND COMPOSITIONS OF CABAZITAXEL 审中-公开
公开(公告)号：WO2019204738A1
公开(公告)日：2019-10-24
申请号：PCT/US2019/028337
申请日：2019-04-19
申请人： ZHUHAI BEIHAI BIOTECH CO., LTD. , SUN, Qun
发明人： SUN, Qun
IPC分类号： A61K31/337 , A61K38/38 , A61P13/08
摘要： This document relates to a composition comprising Cabazitaxel, or a pharmaceutically acceptable salt thereof, human serum albumin, and arginine, or a pharmaceutically acceptable salt thereof, wherein the human serum albumin and the Cabazitaxel, or a pharmaceutically acceptable salt thereof, in the composition have a ratio by weight of no less than 120:1. This document also relates to methods to prepare a composition comprising Cabazitaxel, or a pharmaceutically acceptable salt thereof, human serum albumin, and arginine, or a pharmaceutically acceptable salt thereof, as described herein.

2. 发明申请

WO2011075177A1 INTEGRATED COPOLYETHER GLYCOL MANUFACTURING PROCESS 审中-公开
标题翻译：一体化聚乙二醇制造工艺
公开(公告)号：WO2011075177A1
公开(公告)日：2011-06-23
申请号：PCT/US2010/020699
申请日：2010-01-12
申请人： INVISTA TECHNOLOGIES S.A.R.L. , OSBORNE, Robert, B. , SUN, Qun , SUN, Yanhui , SISLER, Gregg, M. , EISSMANN, Roy, N. , ORLANDI, Robert, D.
发明人： OSBORNE, Robert, B. , SUN, Qun , SUN, Yanhui , SISLER, Gregg, M. , EISSMANN, Roy, N. , ORLANDI, Robert, D.
IPC分类号： C08G65/20 , C08G65/28 , C08G65/30
CPC分类号： C08G65/20 , C08G65/2678 , C08G65/2684 , C08G65/2696 , C08G65/30
摘要： The present invention relates to an improved, fully-integrated continuous process of enhanced process operability for manufacturing copolyether glycols having enhanced physical properties by polymerization of a reaction mixture comprising tetrahydrofuran and at least one alkylene oxide in the presence of an acid catalyst and at least one compound containing reactive hydrogen atoms. The copolyether glycols manufactured by the present process have enhanced physical properties of increased alkylene oxide incorporation, average molecular weight and polydispersity, as well as reduced crystallinity, color, oligomeric cyclic ether content, and linear oligomer having an average molecular weight of up to about 400 dalton content.
摘要翻译：本发明涉及一种改进的，完全一体化的连续方法，其增强了制备具有增强的物理性能的共聚醚二醇的工艺可操作性，所述共聚醚二醇在酸催化剂存在下通过聚合包含四氢呋喃和至少一种烯化氧的反应混合物和至少一种含有活性氢原子的化合物。通过本方法制备的共聚醚二醇具有增加的烯化氧掺入，平均分子量和多分散性以及降低的结晶度，颜色，低聚环醚含量和平均分子量高达约400的线性低聚物的物理性能达尔顿内容

3. 发明申请

WO2010120292A1 IMPROVED CATALYST FOR MANUFACTURING POLYMERS OF TETRAHYDROFURAN 审中-公开
标题翻译：改进四氯化碳聚合物的催化剂
公开(公告)号：WO2010120292A1
公开(公告)日：2010-10-21
申请号：PCT/US2009/040654
申请日：2009-04-15
申请人： SUN, Qun
发明人： INVISTA TECHNOLOGIES S.A.R.L.
IPC分类号： B01J37/10 , B01J31/10 , C08G65/10 , C08G65/20
CPC分类号： C08G65/20 , C08G65/10
摘要： The present invention provides an improved catalyst useful for manufacturing homopolymers and copolymers of tetrahydrofuran, the method for its preparation, and its use as catalyst in a process for manufacturing homopolymers and copolymers of tetrahydrofuran. More particularly, the invention relates to a treated perfluorosulfonic acid resin having the most soluble components reduced by from about 2 to about 20 wt% and an increased average equivalent weight compared to said perfluorosulfonic acid resin prior to treatment, the method for preparing the treated perfluorosulphonic acid resin, and its use as catalyst in a process for manufacturing homopolymers and copolymers of tetrahydrofuran in the presence of said catalyst.
摘要翻译：本发明提供了可用于制造四氢呋喃的均聚物和共聚物的改进的催化剂，其制备方法及其在制备四氢呋喃均聚物和共聚物的方法中作为催化剂的用途。更具体地说，本发明涉及与处理前的所述全氟磺酸树脂相比，其中最易溶解成分减少约2至约20重量％和平均当量增加的处理过的全氟磺酸树脂，制备经处理的全氟磺酸的方法酸树脂，以及其作为在所述催化剂存在下制造四氢呋喃的均聚物和共聚物的方法中的催化剂的用途。

4. 发明申请

WO2010120291A1 COPOLYETHER GLYCOL MANUFACTURING PROCESS 审中-公开
标题翻译：共聚糖制造工艺
公开(公告)号：WO2010120291A1
公开(公告)日：2010-10-21
申请号：PCT/US2009/040647
申请日：2009-04-15
申请人： INVISTA TECHNOLOGIES S.A R.L. , SUN, Qun , ORLANDI, Robert, D.
发明人： SUN, Qun , ORLANDI, Robert, D.
IPC分类号： C08G65/48 , C08G65/26 , C08G65/30 , C08G65/32 , C08G65/00 , C08L71/00
CPC分类号： C08G65/20 , C08G65/2609 , C08G65/2696
摘要： The present invention relates to a continuous process for manufacturing copolyether glycols with high incorporation of alkylene oxide by polymerization of tetrahydrofuran and at least one alkylene oxide in the presence of an acid catalyst, at least one compound containing reactive hydrogen atoms, and a specific diluent or solvent. More particularly, the invention relates to a diluent or solvent-assisted continuous process for manufacturing copolyether glycols with high incorporation of alkylene oxide.
摘要翻译：本发明涉及在酸催化剂，至少一种含有反应性氢原子的化合物和特定的稀释剂存在下，通过四氢呋喃和至少一种烯化氧的聚合，高度引入烯化氧的共聚醚二醇制造方法，溶剂。更具体地，本发明涉及用于制备具有高结合环氧烷的共聚醚二醇的稀释剂或溶剂辅助连续方法。

5. 发明申请

WO2005009987A1 PIPERIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM 审中-公开
标题翻译：哌啶化合物和含有它们的药物组合物
公开(公告)号：WO2005009987A1
公开(公告)日：2005-02-03
申请号：PCT/US2004/023912
申请日：2004-07-23
申请人： EURO-CELTIQUE S.A. , SUN, Qun , WEN, Xin , ZHOU, Xiaoming
发明人： SUN, Qun , WEN, Xin , ZHOU, Xiaoming
IPC分类号： C07D401/04
CPC分类号： C07D417/14 , C07D401/04
摘要： Piperidine Compounds; compositions comprising a Piperidine Compound; and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression in an animal comprising administering to an animal in need thereof an effective amount of a Piperidine Compound are disclosed. In embodiment, the Piperidine Compound has the formula: and pharmaceutically acceptable salts thereof, wherein Ar 1 , Ar 2 , X, R 3 , R 4 , and m are as disclosed herein.
摘要翻译：哌啶化合物; 包含哌啶化合物的组合物; 以及用于治疗或预防疼痛，UI，溃疡，IBD，IBS，成瘾性障碍，帕金森病，帕金森综合征，焦虑，癫痫，中风，癫痫发作，瘙痒症状，精神病，认知障碍，记忆缺陷，限制性脑功能，亨廷顿舞蹈病，肌萎缩性侧索硬化，痴呆，视网膜病变，肌肉痉挛，偏头痛，呕吐，运动障碍或抑郁症，包括向有需要的动物施用有效量的哌啶化合物。在实施方案中，哌啶化合物具有下式及其药学上可接受的盐，其中Ar1，Ar2，X，R3，R4和m如本文所公开。

6. 发明申请

WO2004002983A3 THERAPEUTIC PIPERAZINE DERIVATIVES USEFUL FOR TREATING PAIN 审中-公开
标题翻译：用于治疗疼痛的治疗药物派尼汀衍生物
公开(公告)号：WO2004002983A3
公开(公告)日：2004-03-18
申请号：PCT/US0320509
申请日：2003-06-27
申请人： EURO CELTIQUE SA , KYLE DONALD J , SUN QUN , TAFESSE LAYKEA , ZHANG CHONGWU , ZHOU XIAOMING
发明人： KYLE DONALD J , SUN QUN , TAFESSE LAYKEA , ZHANG CHONGWU , ZHOU XIAOMING
IPC分类号： A61K31/496 , A61P1/00 , A61P1/04 , A61P1/08 , A61P13/02 , A61P17/04 , A61P21/00 , A61P21/02 , A61P25/00 , A61P25/04 , A61P25/06 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/30 , A61P27/02 , A61P29/00 , A61P43/00 , C07D213/74 , C07D213/85 , C07D237/20 , C07D239/42 , C07D241/20 , C07D285/06 , C07D333/16 , C07D401/04 , A61K31/4965 , A61K31/501 , A61K31/506
CPC分类号： C07D213/74 , C07D213/85 , C07D237/20 , C07D239/42 , C07D241/20 , C07D285/06 , C07D333/16
摘要： A compound of formula (I): wherein A, Ar, R , R , and m are disclosed herein, or a pharmaceutically acceptable salt thereof (a "Cyanoiminopiperazine Compound"), cornposition, comprising an effective amount of a Cyanoiminopiperazine Compound, and methods for treating or preventing pain, urinary incontinence, an ulcer, inflammatory-bowel disease, irritable-bowel syndi oine, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke. a sc z are, a prurifc condition, psychosis, a cognitive disorder;`a memory deficit, restricted brain function. R rnfington's chorea., arsiyotrophic lateral sclerosis, dementia, retinopathy, a muscie ,spasm" a migraine, vomiting, dyskinesia or depression in an animal comprising administek irgT b ati animal in need thereof an effective amount of a Cyanoi:irinopiperazine Compound are disclosed.
摘要翻译：式（I）化合物：其中A，Ar，R 3，R 6和m在本文中公开，或其药学上可接受的盐（“氰基亚氨基哌嗪化合物”），包含有效量氰酰亚哌嗪化合物，以及治疗或预防疼痛，尿失禁，溃疡，炎性肠病，肠易激综合征，成瘾性障碍，帕金森病，帕金森综合征，焦虑症，癫痫，中风的方法。是一种瘙痒症状，精神病，认知障碍，记忆障碍，脑功能受限。 Rnfington的舞蹈病，arsiyotrophial侧索硬化症，痴呆症，视网膜病变，肌肉，痉挛“偏头痛，呕吐，运动障碍或抑郁症包括有需要的有效量的Cyanoi 公开了伊立哌嗪化合物。

7. 发明申请

WO1997011081A1 MODIFIED FLUOROSULFONIC ACIDS 审中-公开
标题翻译：改性氟代酸
公开(公告)号：WO1997011081A1
公开(公告)日：1997-03-27
申请号：PCT/US1996014625
申请日：1996-09-12
申请人： E.I. DU PONT DE NEMOURS AND COMPANY , BECKERBAUER, Richard , HARMER, Mark, Andrew , SUN, Qun
发明人： E.I. DU PONT DE NEMOURS AND COMPANY
IPC分类号： C07F07/18
CPC分类号： B01J31/0227 , B01J31/0224 , B01J31/0274 , B01J31/0275 , B01J31/124 , B01J31/127 , B01J31/4007 , B01J31/4015 , B01J2231/14 , B01J2231/323 , B01J2231/324 , B01J2231/4205 , B01J2231/52 , C07B37/02 , C07B41/06 , C07C2/04 , C07C2/66 , C07C5/2266 , C07C5/2562 , C07C45/46 , C07C2531/025 , C07C2531/06 , C07F7/0836 , C07F7/12 , C07F7/1804 , C07F7/1896 , C08G65/20 , C08G77/22 , C08G77/28 , Y02P20/584 , C07C15/50 , C07C11/08
摘要： This invention concerns modified fluorosulfonic acid compounds possessing a sulfonic acid fluoride, chloride or ester group or a sulfonic acid or a salt of a sulfonic acid group at one end and respectively a hydrolyzable or hydrolyzed silane group at the other end, said sulfonic group being adjacent a substantially fluorinated bidentate hydrocarbylene group which is in turn adjacent to a hydrocarbylene group linked to said hydrolyzable or hydrolyzed silane group. Self-condensation of the latter compounds provides novel siloxanes and polysiloxanes. This invention further concerns novel composites comprising a metal oxide network having incorporated therein a group having the formula: -O)qSi(OH)n-qR mR RfSO3Q, and compositions comprising a solid material having a reactive surface to which surface is attached at least one group having the formula: -O)qSi(OH)n-qR mR RfSO3Q.
摘要翻译：本发明涉及在一端具有磺酸氟化物，氯化物或酯基或磺酸或磺酸基的盐，另一端分别具有可水解或水解的硅烷基团的改性氟磺酸化合物，所述磺酸基相邻基本上氟化的二齿亚烃基，其又与连接到所述可水解或水解的硅烷基团的亚烃基相邻。后者化合物的自缩合提供了新的硅氧烷和聚硅氧烷。本发明还涉及包含金属氧化物网络的新型复合材料，其中并入有具有下列结构的基团：-O）qSi（OH）n-qR 1 mR 2 R f SO 3 Q，以及包含具有反应性表面的固体材料的组合物该表面连接至少一个具有下式的基团：-O）qSi（OH）n-qR mR 2 R f SO 3 Q。

8. 发明申请

WO2018081520A1 NEUTRAL PH COMPOSITIONS OF DOCETAXEL AND HUMAN SERUM ALBUMIN 审中-公开
标题翻译：多西他赛和人血清白蛋白的中性PH组合物
公开(公告)号：WO2018081520A1
公开(公告)日：2018-05-03
申请号：PCT/US2017/058697
申请日：2017-10-27
申请人： ZHUHAI BEIHAI BIOTECH CO., LTD. , SUN, Qun
发明人： SUN, Qun
IPC分类号： A61K31/337 , A61K38/38
摘要： This document relates to non-covalently bound complexes including Docetaxel and human serum albumin, and to compositions comprising such complexes. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the composition is a clear aqueous solution when the composition is dissolved in an aqueous solution, and wherein the composition has a solubility in an aqueous solution of at least 10 mg/ml. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. This document also relates to compositions consisting essentially of Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. The pH of the docetaxel compositions of the present disclosure is from about 5 to about 8.
摘要翻译：本文涉及包括多西紫杉醇和人血清白蛋白的非共价结合的复合物，并且涉及包含这种复合物的组合物。该文献还涉及包含多西紫杉醇和人血清白蛋白的组合物，其中当组合物溶解于水溶液中时该组合物是透明的水溶液，并且其中组合物在水溶液中的溶解度为至少10mg / ml。该文献还涉及包含多西紫杉醇和人血清白蛋白的组合物，其中组合物中的多西紫杉醇和人血清白蛋白具有约1:50至约1:1000的重量比。该文件还涉及基本上由多西紫杉醇和人血清白蛋白组成的组合物，其中组合物中的多西紫杉醇和人血清白蛋白具有约1:50至约1:1000的重量比。本公开的多西他赛组合物的pH值为约5至约8

9. 发明申请

WO2018049329A1 FORMULATIONS OF CABOZANTINIB 审中-公开
标题翻译： CABOZANTINIB的制剂
公开(公告)号：WO2018049329A1
公开(公告)日：2018-03-15
申请号：PCT/US2017/050965
申请日：2017-09-11
申请人： ZHUHAI BEIHAI BIOTECH CO., LTD. , SUN, Qun
发明人： SUN, Qun
IPC分类号： A61K9/00 , A61P35/00
摘要： This document relates to compositions comprising a non-covalently bound complex comprising cabozantinib and human serum albumin, wherein the cabozantinib and the human serum albumin in the composition have a ratio by weight from about 1:5 to about 1:2000. This document also relates to compositions comprising cabozantinib and human serum albumin, wherein the cabozantinib and the human serum albumin in the composition have a ratio by weight from about 1:5 to about 1:2000. This document also relates to compositions consisting essentially of cabozantinib and human serum albumin, wherein the cabozantinib and the human serum albumin in the composition have a ratio by weight from about 1:5 to about 1:2000.
摘要翻译：本文涉及包含非共价结合复合物的组合物，所述复合物包含cabozantinib和人血清白蛋白，其中所述组合物中的cabozantinib和人血清白蛋白的重量比为约1:5至约 1：2000。该文件还涉及包含卡洛替尼和人血清白蛋白的组合物，其中组合物中的卡佐坦尼和人血清白蛋白具有约1:5至约1:2000的重量比。该文献还涉及基本上由卡洛替尼和人血清白蛋白组成的组合物，其中组合物中的卡佐苷替尼和人血清白蛋白的重量比为约1:5至约1:2000。

10. 发明申请

WO2013006287A1 IMPROVED METHOD FOR PREVENTING PRESSURE BUILD UP IN A CATALYST SEPARATION SYSTEM 审中-公开
标题翻译：用于防止在催化分离系统中建立压力的改进方法
公开(公告)号：WO2013006287A1
公开(公告)日：2013-01-10
申请号：PCT/US2012/043737
申请日：2012-06-22
申请人： INVISTA TECHNOLOGIES S.A R.L. , GAUSE, Jason, C. , SISLER, Gregg, M. , SUN, Qun
发明人： GAUSE, Jason, C. , SISLER, Gregg, M. , SUN, Qun
IPC分类号： C08G65/00
CPC分类号： C08G65/2696 , Y02P20/584
摘要： A method for preventing pressure build-up across a catalyst separation in a polyether polyol reactor comprising the steps of feeding reactants that comprise a monomer or co-monomers to be polymerized to form the polyether polyol into a continuous feed reactor, flowing the product stream through a catalyst separation system within the reactor, wherein the catalyst separation system is comprised of a plurality of filters, wherein each filter comprises an outer surface and an inner surface defined by a plurality of spaced-apart elements, and wherein the distance between the spaced-apart elements is smaller than the minor dimension of the suspended catalyst and recovering the filtered polyether polyol product and catalyst fines from the reactor outlet.
摘要翻译：一种用于防止在聚醚多元醇反应器中催化剂分离的压力累积的方法，包括以下步骤：将包含待聚合的单体或共聚单体的反应物进料到连续进料反应器中，使产物流通过反应器内的催化剂分离系统，其中催化剂分离系统由多个过滤器组成，其中每个过滤器包括由多个间隔开的元件限定的外表面和内表面，并且其中，分离的元素小于悬浮催化剂的次要尺寸，并从反应器出口回收过滤的聚醚多元醇产物和催化剂细粒。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式